Commonwealth Equity Services LLC Purchases 190 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Commonwealth Equity Services LLC raised its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 4,866 shares of the company’s stock after purchasing an additional 190 shares during the period. Commonwealth Equity Services LLC’s holdings in Krystal Biotech were worth $762,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in KRYS. Swiss National Bank raised its holdings in shares of Krystal Biotech by 8.4% in the fourth quarter. Swiss National Bank now owns 42,400 shares of the company’s stock worth $6,642,000 after buying an additional 3,300 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Krystal Biotech by 31.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,054 shares of the company’s stock valued at $948,000 after acquiring an additional 1,440 shares during the last quarter. Sound View Wealth Advisors Group LLC grew its position in Krystal Biotech by 18.3% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,420 shares of the company’s stock valued at $222,000 after acquiring an additional 220 shares during the last quarter. AlphaQuest LLC increased its stake in Krystal Biotech by 116.0% in the fourth quarter. AlphaQuest LLC now owns 3,020 shares of the company’s stock worth $473,000 after purchasing an additional 1,622 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Krystal Biotech during the fourth quarter worth $15,989,000. Institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on KRYS. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup increased their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Finally, Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $220.00.

Insider Buying and Selling at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Up 3.7 %

Shares of NASDAQ:KRYS opened at $181.00 on Thursday. The firm has a 50 day moving average of $172.47 and a 200 day moving average of $173.31. The company has a market capitalization of $5.21 billion, a price-to-earnings ratio of 60.54 and a beta of 0.75. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. During the same period in the prior year, the business posted $0.30 EPS. The firm’s quarterly revenue was up 116.4% on a year-over-year basis. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).